Prosecution Insights
Last updated: August 15, 2026
Application No. 18/290,241

VINYL ISOCYANIDE COMPOUNDS AS ANTIBACTERIAL AGENTS

Non-Final OA §101§112
Filed
Nov 10, 2023
Priority
May 13, 2021 — GB 2106873.9 +1 more
Examiner
JOHNSON, CHRISTOPHER LINDSAY
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
University of Leicester
OA Round
1 (Non-Final)
52%
Grant Probability
Moderate
1-2
OA Rounds
7m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 52% of resolved cases
52%
Career Allowance Rate
15 granted / 29 resolved
-8.3% vs TC avg
Strong +78% interview lift
Without
With
+77.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
39 currently pending
Career history
73
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
36.1%
-3.9% vs TC avg
§102
21.1%
-18.9% vs TC avg
§112
30.9%
-9.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 29 resolved cases

Office Action

§101 §112
DETAILED ACTION This office action is in response to the Applicant’s filing dated June 15th, 2026. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application is a 371 of PCT/GB2022/051181 filed on May 10th, 2022; and claims benefit of foreign priority of GB2106873.9 filed on May 13th, 2021. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Status of Claims Claims 1-13 and 20-24 are pending in the instant application. Acknowledgement is made of Applicant’s remarks and amendments filed on June 15th, 2026. Acknowledgment is made of Applicant’s amendment of claims 2-13 and 20-24; and the cancelation of claims 14-19 and 25-26. Notice of Change of Examiner Please note that the Examiner prosecuting this application has been changed to Examiner Christopher Johnson of Art Unit 1691. Please address all future correspondences to Examiner Johnson. Election/Restrictions Applicant’s election of Group I in the reply filed on June 15th, 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Applicant’s election without traverse of Compound 38 shown below in the reply filed on June 15th, 2026 is acknowledged: PNG media_image1.png 310 345 media_image1.png Greyscale which is a compound of instantly claimed Formula (I) wherein Y1, Y2 and Y3 are each C-R1, and R1 is H; wherein R1 is H; wherein R2 is R7, specifically PNG media_image2.png 86 91 media_image2.png Greyscale , and R6 is H, and R5 is unsubstituted aryl, specifically phenyl; and wherein R3 and R4 are each H. A prior art search was conducted for the elected species. This compound was found free of prior art. The Examiner did not expand search due to the uncertainties described in the 35 USC § 112(b) rejections below. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-13 and 20-24 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claims 1-13 and 20-24, the instant claims recite formulae and compounds with wavy bond lines as shown below indicated by the arrow: PNG media_image3.png 138 232 media_image3.png Greyscale The meaning of the wavy bond lines are not indicated in the claims, nor in the specification. Thus, the metes and bounds of the claims are unclear. Appropriate action is required. Regarding claim 1, the claim recites “R7 is a group of formula: PNG media_image2.png 86 91 media_image2.png Greyscale ”, but there is no attachment point indicated for the formula of R7, thus the metes and bounds of the claim are unclear. Appropriate action is required. Regarding claims 2-3, the recitation of the phrase "suitably" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Regarding claim 4, the claim recites the phrase "e.g." in parenthesis, which renders the claim indefinite because it is unclear whether the limitations following the phrase “e.g.” in parenthesis are part of the claimed invention. See MPEP § 2173.05(d). Regarding claim 6, the claim recites the limitation "wherein R6 and R7 are independently selected from H, C1 to C6 alkyl, OH, or OR; or R6 and R7 together with the atoms to which they are attached form a substituted or unsubstituted 6 membered ring" in lines 4-6. There is insufficient antecedent basis for this limitation in the claim. Regarding claims 21-23, the language “The compound of claim 1 for use” fails to clearly define the metes and bounds of the claims. Particularly, it is unclear whether the Applicant intended the instant claims to be drawn to a compound or a method of treatment. See MPEP § 2173.05(q). Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 21-23 are rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. Regarding claims 21-23, the claims do not clearly fall within at least one of the four categories of patent eligible subject matter because they are drawn to “The compound of claim 1 for use” as recited in claim 21, which is not one of the four categories of patent eligible subject matter. “One cannot claim a new use per se, because it is not among the categories of patentable inventions specified in 35 U.S.C. § 101") In re Moreton, 288 F.2d 708, 709, 129 USPQ 227, 228 (CCPA 1961). See MPEP § 2173.05(q). Conclusion Claims 1-13 and 20-24 are rejected. No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER L JOHNSON whose telephone number is (571)272-1672. The examiner can normally be reached Monday - Friday 08:00AM - 5:00PM EST with Flex on Fridays. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached on (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /C.L.J./Examiner, Art Unit 1691 /RENEE CLAYTOR/Supervisory Patent Examiner, Art Unit 1691
Read full office action

Prosecution Timeline

Nov 10, 2023
Application Filed
Aug 06, 2026
Non-Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12691111
SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES
3y 11m to grant Granted Jul 28, 2026
Patent 12686682
NEW INDAZOLE ACETYLENE DERIVATIVES
3y 1m to grant Granted Jul 21, 2026
Patent 12649745
AMINO-PYRIMIDINE CYCLO-AMIDES
3y 6m to grant Granted Jun 09, 2026
Patent 12643862
NEW RYLENE DICARBOXIMIDES
3y 10m to grant Granted Jun 02, 2026
Patent 12637426
1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS
4y 1m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
52%
Grant Probability
99%
With Interview (+77.8%)
3y 4m (~7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 29 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month